Otonomy

Otonomy was founded in 2008 by Dr. Jay Lichter, with the mission of advancing medical treatments of ear and hearing related disorders. Dr. Lichter had first hand experience with the lack of available treatment options for inner ear disorders when he had his first vertigo attack. He was later diagnosed with Meniere’s disease. He decided to confront this unmet medical need by founding a company that would seek to change this.

Otonomy is currently running clinical trials for several of its drug candidates for indications ranging from otitis externia to tinnitus. Reparative and regenerative treatment options for sensori-neural hearing loss is under development.

Clinical Trials — Recruiting

Study of OTO-104 in Subjects at Risk From Cisplatin-Induced Hearing Loss

Condition: Cisplatin Induced Hearing Loss
Intervention: Drug: OTO-104
Phase: Phase 2


Study of OTO-104 in Subjects With Unilateral Meniere’s Disease (AVERTS-2)

Condition: Meniere’s Disease
Intervention: Drug: OTO-104; Drug: Placebo
Phase: Phase 3


A 6-Month Extension Study of OTO-104 in Meniere’s Disease

Condition: Meniere’s Disease
Intervention: Drug: OTO-104
Phase: Phase 3


A 6-Month Extension Study of OTO-104 in Meniere’s Disease

Condition: Meniere’s Disease
Intervention: Drug: OTO-104
Phase: Phase 3

Clinical Trials — Active

Open Label Study of OTO-104 in Subjects With Meniere’s Disease

Condition: Meniere’s Disease
Intervention: Drug: OTO-104
Phase: Phase 2


Study of OTO-104 in Subjects With Unilateral Meniere’s Disease (AVERTS-1)

Condition: Meniere’s Disease
Intervention: Drug: OTO-104; Drug: Placebo
Phase: Phase 3

Clinical Trials — Completed

Phase 3 Study of OTO-201 in Acute Otitis Externa

Condition: Acute Otitis Externa; Swimmer’s Ear
Intervention: Drug: 12 mg ciprofloxacin; Drug: Sham Control
Phase: Phase 3


Dose Ranging Study of OTO-201 in AOMT

Condition: Acute Otitis Media; AOMT
Intervention: Drug: 6 mg ciprofloxacin; Drug: 12 mg ciprofloxacin; Other: Sham
Phase: Phase 2


Open-Label Study of OTO-201 in Pediatric Subjects With a History of Otitis Media Requiring Tympanostomy Tubes

Condition: Otitis Media
Intervention: Drug: OTO-201 (ciprofloxacin)
Phase: Phase 3


OTO-201 for the Treatment of Otitis Externa

Condition: Otitis Externa
Intervention: Drug: OTO-201 (ciprofloxacin)
Phase: Phase 2


Open-Label Study of OTO-201 for Treatment of AOMT

Condition: Acute Otitis Media; AOMT
Intervention: Drug: OTO-201
Phase: Phase 2


Open-Label Study of OTO-201 for Middle Ear Effusion Evaluating Trans-Tympanostomy Tube Administration

Condition: Bilateral Middle Ear Effusion
Intervention: Drug: OTO-201
Phase: Phase 3


A 1-Year Safety Study of OTO-104 in Subjects With Unilateral Meniere’s Disease Located in United Kingdom

Condition: Meniere’s Disease
Intervention: Drug: OTO-104; Drug: Placebo
Phase: Phase 2


OTO-201 for the Treatment of Middle Ear Effusion in Pediatric Subjects Requiring Tympanostomy Tube Placement

Condition: Otitis Media With Effusion
Intervention: Drug: OTO-201; Drug: Sham
Phase: Phase 3
Has Results


OTO-201 for the Treatment of Middle Ear Effusion in Pediatric Subjects Requiring Tympanostomy Tube Placement

Condition: Otitis Media With Effusion
Intervention: Drug: OTO-201; Drug: Sham
Phase: Phase 3
Has Results


OTO-201 for Middle Ear Effusion in Pediatric Subjects Requiring Tympanostomy Tube Placement

Condition: Bilateral Middle Ear Effusion Requiring Tympanostomy Tube Placement
Intervention: Drug: OTO-201; Drug: Placebo; Drug: Sham
Phase: Phase 1


OTO-104 for the Treatment of Meniere’s Disease

Condition: Meniere’s Disease
Intervention: Drug: OTO-104; Drug: Placebo
Phase: Phase 2


OTO-104 for Meniere’s Disease

Condition: Meniere’s Disease
Intervention: Drug: OTO-104 (steroid) 3 mg; Drug: Placebo; Drug: OTO-104 (steroid) 12 mg
Phase: Phase 1

RECENT NEWS ON OTONOMY

Nothing Found

Sorry, no posts matched your criteria

COMPANY OVERVIEW

Otonomy

Locations: United States
Year Founded: 2008
CEO: David A. Weber (Ph.D)